Upbeat study results for Idera Pharmaceuticals

Idera Pharmaceuticals Inc. (Nasdaq: IDRA) reported upbeat results from an ongoing Phase 1/2 trial of IMO-8400 to treat patients with Waldenstrom's Macroglobulinemia lifting the stock price 52 cents to close at $4.32.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.